Vivo Capital portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Vivo Capital reported a $1.1 bn portfolio of 47 positions to the SEC as of the end of Q2 2026. Its largest positions are TRVI, PRAX, ERAS. During the quarter it opened Achieve Life Sciences and Editas Medicine and exited Veradermics and Cogent Biosciences.
Sections with a free account
What changed this quarter
23 positions with a change (6 new, 5 added to, 8 trimmed, 4 sold); also, 2 exited through an acquisition or merger, 1 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Erasca−66%fewer sharesReduced16.3% → 6.9%
- Tenax Therapeutics+1,100%more sharesIncreased0.3% → 3.3%
- Arrivent Biopharma+90%more sharesIncreased1.7% → 5.3%
- Tango Therapeutics−36%fewer sharesReduced3.7% → 3.9%
- Abivax+73%more sharesIncreased2.2% → 5.0%
- Praxis Precision Medicines−20%fewer sharesReduced9.1% → 8.3%
- Veradermics−1.6 ppof portfolioSold out1.6% → —
- Achieve Life Sciences+1.5 ppof portfolioNew— → 1.6%
- Cogent Biosciences−1.4 ppof portfolioSold out1.4% → —
- SAB Biotherapeutics−36%fewer sharesReduced3.6% → 2.6%
- DBV Technologies−31%fewer sharesReduced4.6% → 2.8%
- Editas Medicine+1.0 ppof portfolioNew— → 1.1%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Trevi TherapeuticsTRVI8.7%
- Praxis Precision MedicinesPRAX8.3%
- ErascaERAS6.9%
- Arrivent BiopharmaAVBP5.3%
- AbivaxABVX5.0%
- Tango TherapeuticsTNGX3.9%
- Corvus PharmaceuticalsCRVS3.8%
- Bright Minds BiosciencesDRUG3.6%
- Sinovac BiotechSVA3.5%
- Tenax TherapeuticsTENX3.3%
- Aclaris TherapeuticsACRS3.2%
- Dyne TherapeuticsDYN3.2%
- Dianthus TherapeuticsDNTH3.2%
- Alto NeuroscienceANRO2.9%
- DBV TechnologiesDBVT2.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 47
Q2 2026: 52%
Q2 2026: 17.4%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q1 2026 ↗filed May 15, 2026Amendment of May 20, 2026 (replaces the original) ↗
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Opaleye ManagementInvestment firm · $1.1 bn
- Euro Pacific Asset ManagementInvestment firm · $1.1 bn
- Hook Mill Capital PartnersInvestment firm · $1.1 bn
- Ironvine Capital PartnersInvestment firm · $1.1 bn
- Shannon River Fund ManagementInvestment firm · $1.1 bn
- Hudson Way Capital ManagementInvestment firm · $1.1 bn